US 12,447,205 B2
Vaccine molecules
Gunnveig Grødeland, Oslo (NO); Bjarne Bogen, Oslo (NO); and Ane Marie Anderson, Oslo (NO)
Assigned to University of Oslo, Oslo (NO)
Filed by University of Oslo, Oslo (NO)
Filed on Jun. 10, 2024, as Appl. No. 18/738,696.
Application 18/738,696 is a division of application No. 16/645,135, granted, now 12,005,112, previously published as PCT/IB2018/001202, filed on Sep. 7, 2018.
Claims priority of provisional application 62/555,300, filed on Sep. 7, 2017.
Prior Publication US 2024/0325519 A1, Oct. 3, 2024
Int. Cl. A61K 39/145 (2006.01); A61P 31/16 (2006.01); C07K 14/005 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/145 (2013.01) [A61P 31/16 (2018.01); C07K 14/005 (2013.01); C07K 16/2833 (2013.01); A61K 2039/53 (2013.01); A61K 2039/575 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2319/33 (2013.01); C07K 2319/40 (2013.01); C12N 2760/16134 (2013.01)] 21 Claims
 
1. A vaccine composition comprising a mixture of multimeric protein molecules, wherein said mixture of multimeric protein molecules comprise a mixture of at least 3 different fusion protein monomers comprising a targeting unit, a multimerization domain, and an antigenic unit in operable association, wherein said antigenic unit for each of said three different fusion protein monomers differ by encoding different variant target antigenic proteins, and wherein said multimeric protein molecules comprise at least two of said monomers joined by association of said multimerization domains.